Harmony Biosciences Holdings Inc. Common Stock (HRMY)

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinica…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

293

Website

www.harmonybiosciences.com

Fundamentals

1-day range

$39.16$40

Market cap

$2.06B

P/E (trailing)

12.90

P/E (forward)

5.96

EPS (trailing)

$3.09

Dividend yield

—

Beta

0.91

Avg. volume

825.1K

Forecasts

11 analyst ratings

Harmony Biosciences Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• HRMY

  Harmony Biosciences Holdings Inc. Common Stock

  $39.21

  ▼ 1.66%
  Market cap $2.06BP/E 12.90
  $25.52$40.87
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.01BP/E —
  $7.48$18.57
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.13BP/E —
  $14.94$47.65
• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.14BP/E —
  $2.87$9.75
• ZBIO

  Zenas BioPharma Inc. Common Stock

  $31.29

  ▼ 4.08%
  Market cap $1.97BP/E —
  $13.5$44.6
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $1.89BP/E 6.39
  $10.34$19.25
• NBTX

  Nanobiotix S.A. American Depositary Shares

  $41.28

  ▼ 8.59%
  Market cap $1.88BP/E —
  $7.02$47.66

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

52.56M

Total value held

$1.32B

Institutional holders

302